CD8+ T cells as the missing link between doxorubicin cancer therapy and heart failure risk

Abstract

Doxorubicin treatment is a mainstay of cancer therapy but causes potent cardiotoxicity that exposes cancer survivors to the risk of heart failure. A study now identifies CD8+ T cells of the adaptive immune system as major culprits in the development of doxorubicin-induced cardiomyopathy and heart failure.